Literature DB >> 2670382

Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature.

R Hootkins1, A Z Fenves, M K Stephens.   

Abstract

The fluoroquinolones represent a new class of antimicrobial agents with a broad spectrum of activity. We report three cases of acute renal failure following ciprofloxacin in patients without a previous history of renal insufficiency. The average baseline creatinine was 1.1 mg/dl and rose to an average of 4.0 mg/dl during therapy. The length of antecedent ciprofloxacin therapy ranged from several days to several weeks. Other causes of acute renal failure and postobstructive uropathy were excluded. Kidney size was normal-to-increased. Gallium scans were positive in one of two patients studied. Peripheral eosinophilia developed in one case, suggesting an acute hypersensitivity reaction to the drug. The acute renal failure in all cases was non-oliguric and was completely reversed after discontinuation of ciprofloxacin. In two of the three reported cases there was an increased creatinine to BUN ratio, but increased production of creatinine (i.e., rhabdomyolysis) was unlikely with a normal serum creatinine phosphokinase (CPK). In addition, we performed in vitro studies which eliminated the possibility of methodological artifact. The nephrotoxicity of the quinolones has been linked to the development of crystalluria in experimental animals. However, in humans, crystalluria is unlikely and renal damage has not been noted. There have been only two previous case reports of acute renal failure due to oral ciprofloxacin therapy. In one, biopsy showed acute interstitial nephritis. We conclude that oral ciprofloxacin therapy may lead to acute renal failure secondary to tubulointerstitial nephritis characterized by an increased creatinine to BUN ratio. Patients placed on ciprofloxacin therapy need to be followed closely.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2670382

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  18 in total

1.  Andrew Zoltan Fenves, MD: a conversation with the editor. Interview by William Clifford Roberts.

Authors:  Andrew Zoltan Fenves
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-07

2.  Acute renal failure probably induced by prulifloxacin in an elderly woman : a first case report.

Authors:  L Gallelli; A Gallelli; G Vero; F Roccia; G Pelaia; G De Sarro; R Maselli
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 3.  Tolerability of fluoroquinolone antibiotics. Past, present and future.

Authors:  P Ball; G Tillotson
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

4.  Typhoid fever, ciprofloxacin, and renal failure.

Authors:  J Simpson; A R Watson; A Mellersh; C S Nelson; K Dodd
Journal:  Arch Dis Child       Date:  1991-09       Impact factor: 3.791

Review 5.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

6.  Serum sickness-like illness associated with ciprofloxacin.

Authors:  T G Slama
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 7.  Fluoroquinolone-induced renal failure.

Authors:  B M Lomaestro
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

Review 8.  Drug-induced nephrotoxicity. Aetiology, clinical features and management.

Authors:  A J Hoitsma; J F Wetzels; R A Koene
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 9.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

Review 10.  Drug-induced renal calculi: epidemiology, prevention and management.

Authors:  Michel Daudon; Paul Jungers
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.